Nutritional Advice El Mondo
Objectives:
Which treatment is associated with favorable outcomes in COV-2019 patients?
Study design:
This review article included 15 in-vitro and 35 clinical studies including 9,170 COVID-2019 patients.
Results and conclusions:
The investigators found Lopinavir-Ritonavir was significantly associated with shorter mean time to clinical recovery [SMD = -0.32, 95% CI = -0.57 to -0.06].
The investigators found Remdesivir was significantly associated with better overall clinical recovery [RR = 1.17, 95% CI = 1.07 to 1.29].
The investigators found Tocilizumab was associated with less all-cause mortality [RR = 0.38, 95% CI = 0.16 to 0.93].
The investigators found Hydroxychloroquine was associated with longer time to clinical recovery and less overall clinical recovery. It additionally had higher all-cause mortality and more total adverse events.
The investigators concluded meta-analysis suggests that except in vitro studies, no treatment has shown overall favorable outcomes in COVID-2019 patients. Lopinavir-Ritonavir, Remdesivir and Tocilizumab may have some benefits while Hydroxychloroquine administration may cause harm in COVID-2019 patients. Results from upcoming large clinical trials may further clarify role of these drugs.
Original title:
Efficacy of various treatment modalities for nCOV-2019: a systematic review and meta-analysis by Misra S, Nath M, […], Vibha D.
Link:
https://pubmed.ncbi.nlm.nih.gov/32810285/
Additional information of El Mondo:
Find more information/studies on coronavirus right here.